Home The Action Management Committee Finn Olav Levy (NO)

Thu,23Feb2017

Finn Olav Levy, MD, PhD

Professor
Department of Pharmacology,
University of Oslo
Tel.: +47-22840237
Fax: +47-22840202
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Research interests

  • Receptor-mediated signalling in the normal and failing heart
  • G-protein-coupled receptors, especially 5-HT receptors and β-adrenoceptors
  • Compartmentation of cardiac cAMP and cGMP signalling
  • Cardiac cAMP and cGMP phosphodiesterases
  • Natriuretic peptide receptor signalling in the heart

Selected Recent Publications

  • Molenaar P, Christ T, Hussain RI, Engel A, Berk E, Gillette KT, Chen L, Galindo-Tovar A, Krobert KA, Ravens U, Levy FO, Kaumann AJ: Phosphodiesterase PDE3, but not PDE4, reduces β1- and β2-adrenoceptor-mediated inotropic and lusitropic effects in failing ventricle from metoprolol-treated patients. Br. J. Pharmacol. 2013 Mar 12. doi: 10.1111/bph.12167. [Epub ahead of print]
  • Afzal F, Qvigstad E, Aronsen JM,  Moltzau LR, Sjaastad I, Skomedal T, Osnes J-B, Levy FO: Agents increasing cyclic GMP amplify 5-HT4-elicited positive inotropic response in failing rat cardiac ventricle. Naunyn-Schmiedeberg’s Arch. Pharmacol. 384:543-53, 2011
  • Afzal F, Aronsen JM, Moltzau LR, Sjaastad I, Levy FO, Skomedal T, Osnes J-B, Qvigstad E: Differential regulation of β2-adrenoceptor-mediated inotropic and lusitropic response by PDE3 and PDE4 in failing and non-failing rat cardiac ventricle. Br. J. Pharmacol. 162:54-71, 2011
  • Qvigstad E, Moltzau LR, Aronsen JM, Nguyen CHT, Hougen K, Sjaastad I, Levy FO, Skomedal T, Osnes JB: Natriuretic peptides increase β1-adrenoceptor signalling in failing hearts through phosphodiesterase 3 inhibition. Cardiovasc Res. 85:763-72, 2010
  • Kjekshus JK, Torp-Pedersen C, Gullestad L, Køber L, Edvardsen T, Olsen IC, Sjaastad I, Qvigstad E, Skomedal T, Osnes JB, Levy FO: Effect of piboserod, a 5-HT4 serotonin receptor antagonist, on left ventricular function in patients with symptomatic heart failure. Eur. J. Heart Fail. 11:771-8, 2009

ESF

COST

POLICY STATEMENT: Biomedicine and Molecular Biosciences Action BM1005 is funded by COST, through its implementing agent the European Science Foundation.